GE Healthcare (GE) Updates on Results from Two Phase 3s of [18F]flutemetamol
Tweet
Share
E-mailGet Alerts GE Hot Sheet
Join SI Premium – FREE
GE Healthcare (NYSE: GE) announced the preliminary results of two Phase 3 studies of its investigational PET amyloid imaging agent, [18F]flutemetamol, where both studies met their primary endpoints.
One study, in terminally ill patients who agreed to undergo brain autopsy, showed strong concordance between flutemetamol PET images and Alzheimer’s disease-associated beta amyloid brain pathology. The other study, in young healthy volunteers under age 40, had results concordant with the known lack of brain amyloid in this population. Full results of these studies will be presented in the coming months. [18F]Flutemetamol is a GE Healthcare PET imaging agent in development for the detection of beta amyloid.
One study, in terminally ill patients who agreed to undergo brain autopsy, showed strong concordance between flutemetamol PET images and Alzheimer’s disease-associated beta amyloid brain pathology. The other study, in young healthy volunteers under age 40, had results concordant with the known lack of brain amyloid in this population. Full results of these studies will be presented in the coming months. [18F]Flutemetamol is a GE Healthcare PET imaging agent in development for the detection of beta amyloid.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- The West Can't Process Enough of This Critical Metal, and the Gap Doesn't Close by 2030
- Saba Capital funds reapprove merger plan targeting Q4 2026 close
- Virtus Investment Partners names Jack Boyce to its board
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
